ZURA

0.93052.30%
GW

Gary Whale

Chief Technology Officer

Dr. Gary Whale, Ph.D. is a Chief Technology Officer at Zura Bio Limited since March 21, 2023. He served as Partner at Nodenza Venture Partners till December 2024. Gary spearhead the Chemistry, Manufacturing & Control function and is a due diligence powerhouse. He sat on the Investment Committee. Gary has deep industry experience in biotech & pharma. Dr. Whale is a seasoned professional in the pharmaceutical development of biologics. Before joining Zura Bio as Chief Technology Officer and part of the executive management team, Dr. Whale was employed as Vice President, Global Head of Technical Operations at EUSA Pharma, a privately held specialty rare disease company focused on the commercial supply of oncology biologics starting in May 2020. Having nurtured this company through significant growth and profitability, this company was successfully sold in 2022 to a larger Italian specialty care company, Recordati S.p.A. Prior to this, from January 2018 to April 2020, Dr. Whale was Chief Operating Officer at VHsquared, a biotech start-up company specializing the clinical development of treatments focused on autoimmune conditions such as Crohn’s disease and Ulcerative Colitis. From March 2014 to January 2018, Dr. Whale was VP CMC & Manufacturing Operations at VHsquared. During this time a number of global clinical studies were completed and the assets are currently undergoing further phase 2 trials. Previously, Dr. Whale spent a number of years at other companies, such as: Emergent BioSolutions from January 2007 to June 2013, Microscience Ltd from September 2002 to May 2007 and Proctor and Gamble from November 1996 to October 1999, all of which were in a technical operations role. Dr. Whale holds a bachelor’s degree in Biochemistry and a master’s degree in Microbiology from the University of London and a PhD in the purification and characterization of bacterial cell surface antigens from Robert Gordon University.

Positions